As the Ebola outbreak in the Democratic Republic of the Congo expands rapidly, public-health groups and researchers have taken steps to test and deploy existing vaccines to try to curb transmission and reduce deaths. STAT’s Morning Rounds reports that Merck’s Ervebo, a vaccine developed for a different Ebola species, is being put into use as part of a multipronged response.
The international organization that manages the global stockpile of Ervebo agreed to release 70,000 doses for use in the DRC response. According to the report, the allocation is being split: 20,000 doses will be used in a clinical trial setting and 50,000 doses will be given to frontline workers. The decision reflects interest in whether Ervebo might help tamp down transmission or improve survival when deployed against an outbreak driven by a different Ebola species than the one Ervebo was designed to target.
The Coalition for Epidemic Preparedness Innovations (CEPI) is funding multiple studies that will analyze blood samples from people who were previously vaccinated against various Ebola species or against the related Marburg virus. These analyses aim to detect signals of possible cross-protection—immune responses from vaccination against one filovirus that could confer some protection against another. The STAT summary notes these efforts as part of the broader scientific attempt to determine whether existing vaccines can provide any benefit while species-specific candidates are still in development.
Vaccines targeted specifically to the Bundibugyo species of Ebola, which is identified as the cause of the current DRC outbreak, are in development. The article states that some of these candidates are likely still several months away from being available for use, underscoring the time gap between outbreak onset and the availability of species-targeted vaccines.
The STAT report provides outbreak counts through Aug. 18: at least 5,200 confirmed cases and 2,476 deaths among those confirmed cases. These numbers framed the urgency behind deploying available countermeasures such as Ervebo and accelerating research into cross-protective responses and Bundibugyo-specific vaccines.
The Morning Rounds digest also summarized discussion about less aggressive treatment options for prostate cancer. Focal therapy—which targets MRI-visible lesions using heat, cold, electricity, or other energy sources—aims to destroy cancerous tissue without removing the whole gland. Interest in the approach has grown because it may reduce risks of incontinence and erectile dysfunction associated with radical surgery or radiation. The article notes that urologic oncologists remain divided about focal therapy’s benefits. Professional guidelines continue to label the approach experimental, despite its use since the 1990s and recent long-term outcome reports cited in the summary.
STAT highlighted emerging concerns about Meta’s AI-powered smart glasses being used in public and health-care settings. The glasses can discreetly record audio and video, prompting reports of misuse and misconduct in schools, retail settings, and a reported clinical encounter. Experts cited in the summary warn that hands-free recording in clinical environments could create serious patient privacy breaches if sensitive information or diagnoses are captured. The piece notes that similar devices have been banned in some English and Welsh courts on privacy grounds, while some researchers argue hands-free recordings could have educational value, for example in surgical training. The summary poses the question of whether clinics and hospitals will restrict or ban their use.
The digest also presented demographic and policy items. A Human Rights Coalition analysis of Census Bureau data was reported to show that more than 25 million U.S. adults—about 12% of the population—identify as lesbian, gay, bisexual, transgender, or gender diverse. The piece noted ongoing policy actions affecting queer health services and data infrastructure. Separately, the report touched on rapid progress toward powerful new HIV treatments, describing regulatory approvals and the need to plan for social and administrative consequences if treatments substantially change the landscape of HIV care and related benefits programs.
All facts in this summary are drawn from STAT’s Morning Rounds summary of health news. Specific deployment numbers for Ervebo (70,000 total; 20,000 for a trial; 50,000 for frontline workers), CEPI-funded blood-sample analyses, the characterization of Bundibugyo-targeted vaccines as still months away in some cases, and the outbreak counts through Aug. 18 (5,200 confirmed cases; 2,476 deaths) were reported in that source. Other items—on focal therapy, Meta’s glasses, queer population estimates, and HIV treatment policy implications—reflect the same STAT digest. Where the source did not provide additional methodological detail or trial protocols, those specifics were not reported and are not asserted here.